LGND — Merger Agreement between Pelthos Therapeutics and Channel Therapeutics
Jun 1, 2025, 12:00:00 AM UTC
Summary
Ligand Pharmaceuticals' subsidiary Pelthos Therapeutics is set to merge with Channel Therapeutics, with a transaction expected to close in summer 2025.
Company
LIGAND PHARMACEUTICALS INC (LGND)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.ligand.comSimilar Events
Transaction Closing Date
The merger between Ligand Pharmaceuticals and Channel Therapeutics is expected to close in the summer of 2025, enhancing the focus on ZELSUVMI commercialization.
merger closeProposed Merger with Cullgen
Pulmatrix's merger with Cullgen is anticipated to close in the first half of 2025, pending certain closing conditions.
merger closeMedicus to Acquire Antev
Medicus Pharma Ltd. has entered a binding letter of intent to acquire Antev Ltd., with the transaction expected to close by the end of June 2025, pending due diligence and approvals.
merger closeAcquisition Agreement Closing
The acquisition of Crescent Biopharma by GlycoMimetics is expected to close in the second quarter of 2025, pending stockholder approval and customary closing conditions.
merger close